ANIX

Summary

Hold existing ANIX with no adds and no new shorts; keep position size small given binary clinical and financing risk over five trading days. Our analysis awaits confirmation in either direction: an add would require a daily close through middle band resistance with acceptance near the entry zone on stronger volume, momentum above neutral and an expanding histogram toward overhead resistance; a sell or cut would require a close below support on expanding volume or drift toward the lower envelope with loss of short term averages and weakening momentum. Use average range based allowances for noise and avoid outright long options into 306% IV.

The case

Our analysis keeps a neutral basing view on ANIX after a sharp drop in late August to a mid September low, followed by several sessions holding in a tight range into late September on lighter volume versus the capitulation day, closing on a short term average but below middle band and longer term averages. Stabilization lacks bullish confirmation as trend improvement shows a barely positive histogram, momentum recovered from oversold but remains capped below neutral for several sessions, volatility cooled with a rising lower band and only a thin premium over the volume weighted average. Overhead and dilution argue against chasing with stacked resistance and falling longer averages, zero revenue for two years, ongoing quarterly and trailing losses with negative earnings, an elevated book multiple on a thin book value, and a rising share count as issuance funded cash burn, while elevated options caution and a fearful reading on a market fear gauge into 306% IV offset positive social sentiment with a positive retail lean on very light post counts. Stabilization and runway argue against shorting lows with an exhaustion signature on declining volume, stabilizers turning together, cash well above liabilities covering multiple quarters, rising research spending, clustered insider buys in late September adding meaningfully after a sell side trim, plus a first Australian composition patent with long expiry and no fresh clinical or financing catalyst. A prior Sell in mid September faded strength toward resistance for -1.4% alpha and 0% foregone upside, but that edge required strength into resistance; chasing after a -25% drop violates discipline requiring a confirmed breakdown on expanding volume before an outright Sell and a settled close above resistance on stronger volume before adding. Hence we see no edge either way for an immediate order and keep a Hold.

What would weaken it

• Binary clinical/financing risk with zero revenue and ongoing losses
• Overhead resistance and dilution from rising share count
• Elevated 306% IV raises long-option holding costs